Keep up to date with the latest news from Pilatus Biosciences.
October 14, 2025
August 13, 2025
April 29, 2025
April 15, 2025
Yahoo Finance
Leading experts in immunometabolism, immunology, and liver disease to guide advancement of metabolic checkpoint therapies
May 5, 2026
BioWorld
Pilatus Bio Inc. is working to address a major under-addressed target of current checkpoint inhibitors: metabolic stress within solid tumors.
April 28, 2026
Startupticker.ch
Five biotech companies announced recent developments ranging from FDA Fast Track and Orphan Drug designations to the start of Phase 1 and Phase 3 clinical trials. The updates highlight progress in oncology, rare blood disorders, neurodegenerative diseases, multidrug-resistant infections, and Duchenne muscular dystrophy.
March 19, 2026
CancerNetwork
A phase 1 trial evaluating PLT012 in HCC, among other solid tumors, is currently underway and will report safety and preliminary clinical activity data.
February 20, 2026
June 21, 2026
-
San Diego
More Info
June 23, 2026
EHL, Lausanne
June 24, 2026
© 2025 Pilatus Biosciences. All Rights Reserved.